

## European Commission Initiative on Breast Cancer

### Annual Declaration of Interests (ADoI)

**Name: Prof. Dr. med. Annette Lebeau**

Nature of activities	Period	Entity	Subject matter
<b>1. Ownership or financial investments, including shares</b>	NA		
<b>2. Membership of a managing body or equivalent structure</b>	NA		
<b>3. Membership of another scientific advisory body</b>	2001 - Present	- German Cancer Society (Deutsche Krebsgesellschaft e. V.), German Society of Senology (Deutsche Gesellschaft für Senologie e. V.), Berlin	Member of Expert Committee Function of expert: Chair of the Breast Pathology Working Group Function of body: Development of National Guidelines for the Early Detection, Diagnosis and Therapy of Breast Cancer Link to website of body: <a href="http://www.senologie.org/publikationen/leitlinien/">http://www.senologie.org/publikationen/leitlinien/</a>
	12/2009 – Present	- Cooperation alliance mammography (Kooperationsgemeinschaft Mammographie GBR), Berlin	Member of Scientific advisory council Function of expert: Representative for Pathology Function of body: Scientific advice for the Kooperationsgemeinschaft Mammographie Link to website of body: <a href="http://www.mammo-programm.de/">http://www.mammo-programm.de/</a>

Nature of activities	Period	Entity	Subject matter
<b>4a. Employment</b>	05/2006 - Present	Department of Pathology, University Medical Centre Hamburg-Eppendorf (UKE), Hamburg	40% of my working time. My responsibilities are breast and gynaecological pathology, training of residents and students as well as research. The UKE is not involved in the German mammography screening program and the department of pathology does not serve a local screening unit.
<b>4b. Employment (self employed)</b>	06/2006 - Present	Private Group Practice for Pathology, Lübeck	60% of my working time. One of four partners/co-owners. The private group practice offers pathology services that cover the whole spectrum of cytopathology and surgical pathology. Our service for the local mammography screening unit amounts to about 2% of the case number handled in our lab per year. About 20% of my daily work is associated with breast pathology, mainly by serving as a consultant nationwide for second opinion. Only a minor part of this work is associated with mammography screening.

Nature of activities	Period	Entity	Subject matter
<b>5. A. Consultancy/Advisory</b>	2011- Present 2013 – 2015 2013 and 2015  28.8.2011 2013 – Present 2015	<ul style="list-style-type: none"> <li>- Roche Pharma AG, Grenzach-Whylen</li> <li>- Genomic Health Inc., USA</li> <li>- Novartis Pharma AG, Suisse and Germany</li> <li>- Leica Microsystems Ltd., UK</li> <li>- Sysmex Europe, Norderstedt</li> <li>- Menarini Diagnostics</li> </ul>	<p>Consultant and lecture activities            Consultant            Consultant and lecture activities</p> <p>Lecture activities            Consultant            Lecture activities</p> <p>I have been asked for single invited presentations on various subjects of breast and surgical pathology by Roche Pharma AG (2011-present), Leica Microsystems Ltd (2011), Novartis (2015) and Menarini Diagnostics (2015) on the occasion of scientific meetings. The fees payed by the companies covered my travel expenses and partly compensated my absence from work. Additionally, I have been asked to perform scientific advisory services for Roche Pharma AG (2014-present), Genomic Health Inc. (2013-2015), Novartis Pharma AG (2013) and Sysmex Europe (2013-present) by attending single National or European Pathology or Oncology Advisory Board Meetings. The fees covered my travel expenses and partly compensated my absence from work.</p> <p>None of the lectures or advisory services concern mammography screening. The key aspects are the identification of predictive markers for breast cancer treatment, especially targeted therapies.</p>
<b>5. B. Consultancy/Advisory</b>	2005 - Present	Reference Centre for Mammography Screening Munich in collaboration with the Academy for Training in Morphology e. V. (Akademie für Fortbildung in der Morphologie e. V.)	<p>Course instructor for the training of pathologists in the German mammography screening program.            The lectures are paid by the Academy for Training in Morphology e. V. (Akademie für Fortbildung in der Morphologie e. V.)</p>

Nature of activities	Period	Entity	Subject matter
<b>5. C. Consultancy/Advisory</b>	2007 - Present	Reference Centres for Mammography Screening North and Munich	I am appointed reference pathologist in the German mammography screening program performing reference services for two of the five reference centers that are responsible for quality assurance, training and accompanying research. The activity as reference pathologist is honorary and not compensated by a fixed salary.
<b>6. Influence on definition of research priorities</b>	NA		
<b>7. Research grants and other funding</b>	NA		

Nature of activities	Period	Entity	Subject matter
<b>8. Principal investigator or investigator</b>	2011 – Present	- Sysmex Europe, Norderstedt	Principal Investigator: Performance Evaluation of the SYSMEX RD-100i Nucleic Acid Amplification System for the Detection of Lymph Node Metastases In Breast Cancer Patients as Part of the SENTINA (SENTInel NeoAdjuvant) Trial. The study is sponsored by Sysmex.
	2015 – Present	- BioNTech Diagnostics GmbH, Mainz	Participant in “An International MammaTyper™ Reproducibility Study”. MammaTyper™ is a molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue. The study is sponsored by BioNTech Diagnostics GmbH
	2016 - Present	- Roche Pharma AG, Granzach-Wyhlen	Participant in « EPI HER2 BC study (ClinicalTrials.gov ID: NCT02666261) », a noninterventional, prospective study of variables influencing HER2-positivity in breast cancer in Germany. The study is sponsored by Roche Pharma AG
<b>9. Intellectual property rights (IPR)</b>	NA		
<b>10. Other membership or affiliation</b>	NA		
<b>11. Interests of others</b>	NA		
<b>12. Other</b>	NA		

I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge.

Should there be any change to the above information, I will promptly notify the responsible service of the Commission and complete a new DoI form including the changes.

Done at: Lübeck

Date: 28.01.2018

Signature: 